AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03060577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inclisiran
Description: Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
Study NCT02703961 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: pelvic radiotherapy
Description: external beam radiotherapy for whole pelvix with 50Gy/25f boost radiotherapy for pelvic lymph node metastasis with 12-14Gy/4-7f.
Study NCT02703961 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: brachytherapy
Description: CT/MRI guided brachytherapy or x-ray guided brachytherapy
Study NCT03060577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evolocumab
Description: Evolocumab is a fully human monoclonal antibody that inhibits PCSK9.
Study NCT00986193 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transapical Aortic Valve Implantation
Description: Insertion of a stent valve using catheter-based technique through a mini thoracotomy
Study NCT00986193 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Aortic Valve Surgery
Description: Operation using heart-lung machine, with insertion of a biological artificial heart valve
Study NCT04251312 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Hygiene Education and Oral Hygiene Packets
Description: Patients will be educated on oral hygiene and will be given packets containing toothpaste, mouth rinse, floss and a toothbrush
Study NCT00523666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Galantamine (Reminyl®)
Description: 8mg - 24mg
Study NCT00523666 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/Galantamine (Reminyl®)
Description: Patients are treated double-blind with placebo for 6 months, followed by treatment with Galantamine (Reminyl®) for another 6 months.~Dose scheme: 8mg-24mg
Study NCT01927289 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Proximal Brachial Plexus vs Distal Forearm Block
Description: Proximal Brachial plexus block: 15 mls saline injected in distal forearm nerve block and 15 mls of 1.5% Mepivacaine injected to the brachial plexus via the supraclavicular approach.~Distal forearm block: 15 mls 1.5% Mepivacaine injected in distal forearm nerve block and 15 mls of saline injected to the brachial plexus via the supraclavicular approach
Study NCT02641704 — intervention group
Intervention type: BEHAVIORAL
Intervention: Multidisciplinary program
Description: Coordinated multidisciplinary program
Study NCT02333331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimagrumab
Description: Bimagrumab will be administered as an intravenous infusion starting on Day 1 until week 21.
Study NCT02333331 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will be administered as an intravenous infusion starting on Day 1 until week 21.
Study NCT01902719 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication Skills Training
Description: Receipt of Do My PART (P-Prepare for Visit, A- Act at visit, R-Review doctor's recommendations, T-Take home recommendations)communication skills training.
Study NCT01902719 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Skills Training
Description: Receipt of a 9-week group based self-management intervention designed to help patients identify and solve self-identified barriers to hypertension control.
Study NCT00134537 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interspinous process and dynamic stabilization
Description: Interspinous process and dynamic stabilization
Study NCT00134537 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative Care
Description: Medication, exercise and spinal injections
Study NCT00842062 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyoScience Tissue Remodeling Device
Description: Percutaneous treatment with the MyoScience device
Study NCT01728636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic Acid
Description: intravenous administration of bolus and infusion for duration of surgical procedure
Study NCT01728636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: intravenous administration of bolus and infusion for duration of surgical procedure
Study NCT01253564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5185426
Description: 960 mg b.i.d. orally
Study NCT01442285 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: personalized, motivational messages
Description: A Healthcare Provider Report will be printed after each assessment and reviewed by the subject's oncologist. If any mental health functioning scale scores fall in the elevated or high range, a treatment plan will be constructed. Subjects will receive a personalized Patient Feedback Report after each assessment which will include motivationally tailored messages and suggestions for action.
Study NCT02676622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mobilization of stem cells to prepare for Leukapheresis
Description: Cyclophosphomide 2 g/m2 x 2 consecutive days.~Filgrastim (G-csf) 10 mcg/kg SC will start 5 days after the last dose of CY and will end the day before the last leukapharesis.
Study NCT02676622 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leukapheresis- Collection of stem cells
Description: Placement of an Apheresis Catheter on the day of collection of stem cells.~Leukapheresis will be performed on a continuous flow separator machine to target 3-8 x 106 CD34+ cells/kg body weight.
Study NCT01186835 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combination Botulinum Toxin A and Hyaluronic Acid
Description: One side of subject's face will randomly be assigned combination treatment.
Study NCT02703961 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Description: CT/MRI guided brachytherapy or x-ray guided brachytherapy
Study NCT01186835 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin A
Description: Other side of subjects face with receive Botulinum Toxin A treatment alone.
Study NCT03420482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant (FMT) oral capsules
Description: Donors will be healthy individuals, selected through a previously published, rigorous screening process. Elizabeth Hohmann M.D. of MGH has demonstrated the safety and therapeutic efficacy of oral frozen FMT capsules in Clostridium difficile infection, and her lab will produce the capsules for this study.
Study NCT02703961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjuvant chemotherapy with cisplatin and docetaxel
Description: cisplatin 75mg/m2, d43,d64; docetaxel 75mg/m2, d43,d64
Study NCT02505139 — intervention group
Intervention type: OTHER
Intervention: the number of circulating tumor cells
Study NCT03188328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AvidinOX
Description: AvidinOX vial containing 22.5 mg AvidinOX~+ vials containing 10 ml of water for injection (WFI) for the reconstitution in a clear solution with an AvidinOX concentration of 3 mg/ml. One Intralesion administration of a volume of reconstituted AvidinOX equal to about 15 % of the estimated lesion volume
Study NCT03188328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-ST2210
Description: 177Lu-ST2210 dose starting at 7.5 Gigabequerel (GBq) ±10%with escalation steps of 2.5 GBq up to 15 GBq ±10%, approximately 1 mg ST2210
Study NCT03188328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-ST2210
Description: Second dose of 177Lu-ST2210 dose (14 days after the first dose) starting at 7.5 Gigabequerel (GBq) ±10%with escalation steps of 2.5 GBq up to 15 GBq ±10%, approximately 1 mg ST2210
Study NCT03228199 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intervention group
Description: Will immediately receive a free pair of presbyopic glasses through the Clear Vision Workplace program. These glasses will correct the worker's vision at their usual working distance, and will not correct astigmatism.
Study NCT03228199 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Will be deferred to receive spectacles as above, after the 12 week evaluation period.
Study NCT03420482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Oral placebo capsules filled with glycerol and cocoa powder. These capsules are identical in appearance to FMT capsules.
Study NCT04161898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Upadacitinib will be administered as oral tablet
Study NCT04161898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Upadacitinib
Description: Placebo for upadacitinib will be administered as oral tablet
Study NCT04161898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone will be administered as oral tablet
Study NCT01945762 — intervention group
Intervention type: DRUG
Intervention: Vandetanib 300 mg
Description: Vandetanib commercial tablets
Study NCT00343681 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine (split virion)
Description: 0.5 mL, Intramuscular
Study NCT01634139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium low dose QD
Description: 2 actuations once daily in the evening
Study NCT01634139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium high dose QD
Description: 2 actuations once daily in the evening
Study NCT01634139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 actuations once daily in the evening
Study NCT04026815 — intervention group
Intervention type: OTHER
Intervention: medical history, blood and urine tests
Description: The study protocol consists of questionnaires (medical, socio-economic, dietary), comprehensive geriatric assessment, physical examination, anthropometric and blood pressure measurements and laboratory tests.
Study NCT04275895 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluation of different attention or/and postural activities
Description: 1. The children, equipped with a head-mounted display (HMD), will indicate as quickly as possible the direction of a fish that can be surrounded by congruent or not flankers (Inhibition) and/or preceded by signal (Alert)~2. The children, equipped with a HMD and a joystick, will vertically turn a randomly inclined stick~3. The children will stand on a force plate watching a cartoon, gazing a fixation cross or eyes closed~4. The children, equipped with an augmented reality headset, will perform 2 levels of difficulty of 3 attention tasks standing on a force plate:~   * They will click as quickly as possible when they see a frog among successively appearing animals (vigilance task)~  * They will give the name of an animal appearing at one of the windows displayed (visual search task)~  * They will count the number of yellow lions oriented to the right among several animals of different color and direction (inhibition task)~5. Growth trajectory will be retrieved from health booklet
Study NCT04275895 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of different attention or/and postural activities
Description: 1. The children, equipped with a head-mounted display (HMD), will indicate as quickly as possible the direction of a fish that can be surrounded by congruent or not flankers (Inhibition) and/or preceded by signal (Alert)~2. The children, equipped with a HMD and a joystick, will vertically turn a randomly inclined stick~3. The children will stand on a force plate watching a cartoon, gazing a fixation cross or eyes closed~4. The children, equipped with an augmented reality headset, will perform 2 levels of difficulty of 3 attention tasks standing on a force plate:~   * They will click as quickly as possible when they see a frog among successively appearing animals (vigilance task)~  * They will give the name of an animal appearing at one of the windows displayed (visual search task)~  * They will count the number of yellow lions oriented to the right among several animals of different color and direction (inhibition task)~5. Growth trajectory will be retrieved from health booklet
Study NCT01050556 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily, 24 weeks
Study NCT01050556 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: folic acid
Description: 400 ug/d for 12 or 24 weeks
Study NCT01050556 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: folic acid
Description: 800 µg/d for 12 or 24 weeks
Study NCT01050556 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: creatine
Description: 3 mg/d for 12 weeks
Study NCT01050556 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: creatine + folic acid
Description: 3 mg creatine/d + 400 µg folic acid/d for 12 weeks
Study NCT00633672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 20mg Oral tablet once daily
Study NCT03816670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corifollitropin Alfa
Description: late start (day 4) vs. corifollitropin-alfa standard start (day 2)
Study NCT03252340 — intervention group
Intervention type: DRUG
Intervention: ADSTEM Inj.
Description: 1. ADSTEM Inj. 1.0x10\^8 mesenchymal stem cells as an intravenous infusion once in Phase I clinical trial.~2. ADSTEM Inj. 3.0x10\^8 mesenchymal stem cells as an intravenous infusion once in Phase I clinical trial.
Study NCT01985854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Study NCT01985854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Study NCT03603509 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluad Vaccine
Description: FLUAD is an inactivated influenza vaccine indicated for active immunization against influenza. disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUAD is. approved for use in persons 65 years of age and older.
Study NCT03603509 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone High-Dose
Description: FLUZONE® HIGH-DOSE vaccine is indicated for people 65 years of age and older to help prevent influenza disease caused by influenza A and B strains contained in the vaccine.
Study NCT02574572 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal cells transplantation
Description: All patients will undergo laminectomy and autologous mesenchymal cells injection into the lesion area.
Study NCT01097876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04447943 25 mg
Description: 25 mg PF-04447943 BID for 7 days (period 1) 7 day washout (no drug) 7 days of 5 mg donepezil QD; 14 days 10 mg QD (Period 2) 7 days of 10 mg donepezil QD and 25 mg PF-04447943 BID (Period 3)
Study NCT01097876 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PF
Description: Placebo BID for 7 days (period 1) 7 day washout (no drug) 7 days of 5 mg donepezil QD; 14 days 10 mg QD (Period 2) 7 days of 10 mg donepezil QD and Placebo BID (Period 3)
Study NCT00633672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranitidine
Description: 150mg oral twice daily
Study NCT00633672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 40mg oral tablet once daily
Study NCT04438070 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: COVID-19 Swab
Description: Nasal, Oral-Nasal combined or Nasopharyngeal swab
Study NCT02676622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preparative regimen 4-6 weeks after Leukapheresis
Description: Prior to starting medicines, a central venous line will be placed (arm or chest)~Cyclophosphamide iv: 50 mg/kg iv over 2 hours~Mesna iv (uro-protectant): 36 mg/kg iv over 12 hours~r-ATG (Thymoglobulin, Genzyme): 2.5 mg/kg/dose iv over 6 hours on days -3,-2,-1
Study NCT02676622 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Infusion of the(cryopreserved and thawed)peripheral blood stem cells (PBSC)occurs on Day 0.~Day +5: start Filgrastim (G-csf) subcutaneous injections~Hospitalization in isolation room for 4-5 weeks
Study NCT02676622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose IL-2 administration
Description: IL-2 Subcutaneous injections will start once ANC is > 500/µL and patient is afebrile (start IL-2 will be approximately day +20)for 6 weeks of treatment.~Once patient or parent has learnt the administration and patient is tolerating it well, then the rest of the treatment can be administered at home after discharge with weekly follow up visits.
Study NCT02944825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: first line prophylactic oral antibiotic
Study NCT02944825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trimethoprim/sulfamethoxazole
Description: second line prophylactic oral antibiotic
Study NCT02944825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No Intervention
Description: No intervention
Study NCT04607785 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Miswak mouthwash group
Description: Twice daily for seven days for two months
Study NCT04607785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Miswak mouthwash group
Description: Twice daily for seven days for two months
Study NCT04607785 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Chlorhexidine gluconate mouthwash
Description: Twice daily for seven days for two months
Study NCT04607785 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate mouthwash
Description: Twice daily for seven days for two months
Study NCT02569905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: parecoxib sodium
Description: parecoxib sodium 40mg
Study NCT04438070 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: COVID-19 Swab
Description: Nasal, Oral-Nasal combined or Nasopharyngeal swab
Study NCT03272789 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Interviews with coach
Description: For Interviews : done at Day 0 and at 1, 2, 3, 6 and 12 months. Questionnaires : given at Day 0, and at 3, 6 and 12 months.
Study NCT02569905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: flurbiprofen
Description: flurbiprofen 50mg
Study NCT02569905 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: normal saline
Study NCT01733888 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Office Bleaching
Description: Teeth will be cleaned with pumice first, followed by placing cheek retractors and covering of the lip surface with petroleum gel. Thereafter, teeth will be dried and gingival barrier will be applied to both arches - slightly overlapping enamel and interproximal spaces. Light curing of the gingival barrier will be done in a fanning motion for 10-20 seconds. This is followed by homogeneous mixing of the powder and liquid in a powder pot the application of a thick layer of the resulting gel to all teeth undergoing treatment (35 % Hydrogen Peroxide, Pola Office, SDI, Australia). The gel will be left in place for 8 minutes and subsequently removed using a surgical aspirator tip.
Study NCT01733888 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resin Infiltration
Description: Fluorosed teeth will be isolated using a rubber dam and the resin infiltrant (Icon, DMG, Hamburg, Germany) will be applied as per manufactures' instructions. In short, tooth surface will be dried using cotton rolls and air syringe. This is followed by an etching (Icon Etch) and drying step (Icon-Dry) to open the lesion surface. Resin infiltrant will then be applied and allowed to seep in for 3 minutes followed by light curing for 40 seconds and subsequent cleaning of the surface with pumice and rubber polishing cup as well as rinsing with water for 30 sec.
Study NCT01733888 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resin Infiltration twice
Description: The intervention will be done similar to the Resin infiltration arm, which the exception that the icon infiltration step will be done twice.
Study NCT01733888 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bleaching + Resin Infiltration
Description: In this arm, the fluorosed teeth of the patients will first be bleached using 35 % Hydrogen Peroxide (Pola Office, SDI, Australia) as explained in the intervention arm Office bleaching; followed by wash over period of 20 days. After these 20 days, patients will be recalled and the fluorosed teeth will treated according to the description in the Resin infiltrant intervention arm using the resin infiltrant (Icon, DMG, Hamburg, Germany) as per manufactures' instructions.
Study NCT01326936 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online education
Description: A brief (2-hour) interactive online training program in substance abuse (SU) management using virtual patient (VP) technology. Each learner will take one of two similar online programs involving five VPs that represent the range of SU management issues that commonly arise in clinical practice.
Study NCT01000038 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wii-Fit intervention
Description: Half hour daily, 5 days a week for 8 weeks
Study NCT01000038 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking
Description: Half hour daily, five days a week for 8 weeks
Study NCT01000038 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking
Description: Half hour daily, five days a week for 8 weeks